On 25 July 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the addition of a new formulation to the marketing authorisation of the medicinal product Insuman. The new formulation, Insuman Implantable, is an insulin solution for infusion (400 IU/ml) that is delivered into the intra-peritoneal cavity via an implantable pump device (MiniMed). It has been developed as a replacement for another insulin product called Insuplant, which is no longer manufactured
read at
http://www.pharmaintellect.com/2013/07/sanofi-gets-eu-chmp-nod-for-new.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmainvest+%28PharmaInvest%29
